Pharmaceuticals

Growth In The Drug Repositioning Service Market Is Being Driven By Expansion & Healthcare Infrastructure Development Driving The Growth Due To Increased Hospital Capacity And Service Utilization

April 30, 2026April 30, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Are The Market Size Estimates For The Drug Repositioning Service Market In 2026 And 2030?

The drug repositioning service market size has demonstrated robust expansion over recent years. It is projected to increase from $34.2 billion in 2025 to $36.19 billion in 2026, registering a compound annual growth rate (CAGR) of 5.8%. The historical growth of this market can be attributed to several factors, including rising pharmaceutical R&D costs, the availability of extensive legacy drug data, a growing number of failed clinical trials, the increasing demand for faster drug development cycles, and the early adoption of computational drug discovery.

The drug repositioning service market is anticipated to experience robust expansion over the coming years. This market is projected to reach $45.92 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.1%. This anticipated growth is driven by factors such as a heightened need for economical drug development, the growing integration of AI-powered discovery tools, an intensified emphasis on rare and orphan conditions, the broadening scope of data-informed clinical research, and a greater acceptance of repurposed drugs by regulatory bodies. Key developments expected during this forecast period encompass the increasing application of AI-driven drug repurposing platforms, a heightened emphasis on re-evaluating drugs that failed in clinical trials, the expanding incorporation of real-world data into drug discovery processes, the proliferation of precision medicine-focused repositioning strategies, and strengthened partnerships between pharmaceutical companies and contract research organizations (CROs).

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=29040&type=smp

What Key Factors Are Affecting The Drug Repositioning Service Market Demand?

The projected growth of the drug repositioning service market is expected to be propelled by rising healthcare expenditures. Healthcare expenditures represent the comprehensive financial outlay on health services, encompassing aspects like prevention, treatment, rehabilitation, and administration. These expenditures are primarily increasing due to escalating medical costs, which are driven by advancements in technology and the expanding demand for healthcare services. Elevated healthcare spending positively impacts drug repositioning services because increased funding facilitates more clinical trials and research, thereby accelerating the identification of new therapeutic uses for existing drugs. For instance, in May 2024, the Office for National Statistics, a UK-based Government department, indicated that total healthcare expenditure saw a notable rise of 5.6% in nominal terms from 2022 to 2023. Thus, the increase in healthcare expenditures is a key driver for the drug repositioning service market’s expansion.

What Are The Key Segment Divisions In The Drug Repositioning Service Market Segment Structure?

The drug repositioning service market covered in this report is segmented –

1) By Type: Generic Drugs, Clinical Trial Failed Drugs

2) By Therapeutic Area: Oncology, Neurology, Infectious Diseases, Cardiovascular Diseases, Other Therapeutic Area

3) By End-User: Pharmaceutical Companies, Biotechnology Firms, Contract Research Organizations (CROs), Academic Research Institutions, Hospitals And Ambulatory Surgical Centers.

Subsegments:

1) By Generic Drugs: Small Molecule Drugs, Biologics, Biosimilars, Peptide-Based Drugs

2) By Clinical Trial Failed Drugs: Phase I Failed Drugs, Phase II Failed Drugs, Phase III Failed Drugs, Safety-Related Failed Drugs, Efficacy-Related Failed Drugs

What Market Trends Are Affecting The Drug Repositioning Service Market?

Leading companies in the drug repositioning service market are increasingly embracing artificial intelligence (AI) for drug repositioning, particularly through computational systems that leverage AI for systematic analysis of literature and biological data to identify novel therapeutic uses for existing medications. A computational drug repositioning system is essentially a technology-powered platform that utilizes AI, machine learning, and data mining techniques to thoroughly examine existing drugs, compounds, and biological information. For instance, in November 2024, the Japanese firms UBE and FRONTEO initiated a collaborative co-creation project. This project establishes a joint framework that combines the specialized knowledge of both UBE and FRONTEO to bolster drug repositioning efforts. It facilitates smooth integration between dry research (data analysis) and wet research (biological testing), thus improving the progression from initial hypothesis generation to experimental confirmation. By employing FRONTEO’s AI-powered Drug Discovery AI Factory and KIBIT technology, the initiative methodically uncovers previously undiscovered connections between diseases and molecules.

Which Organizations Are Engaged In The Drug Repositioning Service Market?

Major companies operating in the drug repositioning service market are Recursion Pharmaceuticals Inc., Excelra, LifeArc, Cosmos Health Inc., Fios Genomics, Insilico Medicine Inc., Melior Discovery, Delta4, Acubiosys, VeriSIM Life, BioXcel Therapeutics Inc., Pharnext S.S., NuMedii, GVK Biosciences, Plex Research, Paradigm Biopharmaceuticals, BenevolentAI Limited

Get The Full Drug Repositioning Service Market Report:

https://www.thebusinessresearchcompany.com/report/drug-repositioning-service-global-market-report

Which Region Is The Leading Market For The Drug Repositioning Service Market?

North America was the largest region in the drug repositioning service market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug repositioning service market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Drug Repositioning Service Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/drug-repositioning-service-global-market-report

Browse Through More Reports Similar to the Global Drug Repositioning Service Market 2026, By The Business Research Company

Drug Discovery Services Market Report 2026

https://www.thebusinessresearchcompany.com/report/drug-discovery-services-global-market-report

Controlled Substance Market Report 2026

https://www.thebusinessresearchcompany.com/report/controlled-substance-global-market-report

Behavioral Rehabilitation Market Report 2026

https://www.thebusinessresearchcompany.com/report/behavioral-rehabilitation-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795